axicabtagene ciloleucel
daiichi sankyo,gilead
['lymphoma', 'axi-cel']
axi-cel has demonstrated promising efficacy and acceptable safety as a second-line treatment in patients with r/r aggressive b-cell lymphomas who are ineligible for hdc and asct, according to data from a phase 2 clinical trial presented at #ash22 more: 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.